-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Aa5SS4gNa6Tyv9qAiPo1g/Z/7KFUmnVpTE1SBn83lGut+JKCbO0Dn0KCKPzx8Jt4 G99qhJa5jrqPB35ADDOVUg== 0000950133-98-003960.txt : 19981120 0000950133-98-003960.hdr.sgml : 19981120 ACCESSION NUMBER: 0000950133-98-003960 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 19981119 GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH TARGET S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALGOS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000924862 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223142274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-48097 FILM NUMBER: 98755552 BUSINESS ADDRESS: STREET 1: 4900 ROUTE 33 CITY: NEPTUNE STATE: NJ ZIP: 07753 BUSINESS PHONE: 9089385959 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13G 1 SCHEDULE 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ___________)* ALGOS PHARMACEUTICAL CORPORATION ------------------------------------------------------------------------ (Name of Issuer) COMMON STOCK, PAR VALUE $.01 PER SHARE ------------------------------------------------------------------------ (Title of Class of Securities) 015869 10 0 ------------------------------- (CUSIP Number) NOVEMBER 9, 1998 ------------------------------------------------------------------------ (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) 2 CUSIP No. 015869 10 0 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BB BIOTECH AG - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Switzerland - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each ----------------------------------------------------------------- Reporting 6. Shared Voting Power Person With: 1,000,000 ----------------------------------------------------------------- 7. Sole Dispositive Power -0- ----------------------------------------------------------------- 8. Shared Dispositive Power 1,000,000 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,000,000 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 5.9% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) HC, CO - -------------------------------------------------------------------------------- Page 2 of 9 pages 3 CUSIP No. 015869 10 0 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BIOTECH TARGET S.A. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization PANAMA - -------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each ----------------------------------------------------------------- Reporting 6. Shared Voting Power Person With: 1,000,000 ----------------------------------------------------------------- 7. Sole Dispositive Power -0- ----------------------------------------------------------------- 8. Shared Dispositive Power 1,000,000 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,000,000 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 5.9% - -------------------------------------------------------------------------------- 12. Type of Reporting Person CO - -------------------------------------------------------------------------------- Page 3 of 9 pages 4 ITEM 1. (a) Name of Issuer Algos Pharmaceutical Corporation (b) Address of Issuer's Principal Executive Offices 1333 Campus Parkway Neptune, NJ 07753-6815 ITEM 2. (a) Name of Person Filing BB Biotech AG ("BB Biotech") Biotech Target S.A. ("Biotech Target") (b) Address of Principal Business Office or, if none, Residence BB Biotech Biotech Target Vordergasse 3 Swiss Bank Tower 8200 Schaffhausen Panama 1 CH/Switzerland Republic of Panama (c) Citizenship See Item No. 4 of cover pages. (d) Title of Class of Securities Common Stock, Par Value $. 01 Per Share (e) CUSIP Number 015869 10 0 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) [] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). Page 4 of 9 pages 5 (c) [] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii) (E); (f) [] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J). ITEM 4. OWNERSHIP Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 1,000,000 (b) Percent of class: 5.9% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote -0- (ii) Shared power to vote or to direct the vote 1,000,000 Page 5 of 9 pages 6 (iii) Sole power to dispose or to direct the disposition of -0- (iv) Shared power to dispose or to direct the disposition of 1,000,000 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON. Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY This statement is filed jointly by BB Biotech and Biotech Target. Biotech Target is a wholly-owned subsidiary of BB Biotech. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable. ITEM 9. NOTICE OF DISSOLUTION OF GROUP Not applicable. ITEM 10. CERTIFICATION By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 6 of 9 pages 7 SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: November 19, 1998 By: /s/ HANS-JOERG GRAF ------------------------------- Name: Hans-Joerg Graf ------------------------------- Signatory Authority Date: November 19, 1998 By: /s/ DR. VICTOR BISCHOFF ------------------------------- Name: Dr. Victor Bischoff ------------------------------- Vice Chairman and Director BIOTECH TARGET S.A. Date: November 19, 1998 By: /s/ DR. ANDREAS BREMER ------------------------------- Name: Dr. Andreas Bremer ------------------------------- Signatory Authority Date: November 19, 1998 By: /s/ DR. ANDERS HOVE ------------------------------- Name: Dr. Anders Hove ------------------------------- Signatory Authority Page 7 of 9 pages 8 EXHIBIT INDEX Exhibit 1: Translation of minutes of the October 18, 1995, Board of Directors Meeting of Biotech Target (evidencing a power of attorney in favor of Dr. Andreas Bremer).* Exhibit 2: Translation of minutes of the January 3, 1997 Board of Directors Meeting of Biotech Target (evidencing a power of attorney in favor of Dr. Anders Hove).* Exhibit 3: Translation of evidence of a power of attorney in favor of Victor Bischoff and Hans-Joerg Graf on behalf of BB Biotech.** Exhibit 4: Agreement by and between BB Biotech and Biotech Target with respect to the filing of this disclosure statement. - --------------------- * See Powers of Attorney, previously filed as Exhibits 1 and 2 to the Schedule 13D related to Alexion Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 18, 1997, which Exhibits are incorporated by reference herein. ** See Power of Attorney, previously filed as an Exhibit 99.E to the Schedule 13D relating to Biogen, Inc. filed with the Securities and Exchange Commission on June 2, 1994, which Exhibit is incorporated by reference herein. Page 8 of 9 pages EX-4 2 JOINT FILING AGREEMENT 1 EXHIBIT 4 JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB BIOTECH AG Date: November 19, 1998 By: /s/ HANS-JOERG GRAF ------------------------------- Name: Hans-Joerg Graf ------------------------------- Signatory Authority Date: November 19, 1998 By: /s/ DR. VICTOR BISCHOFF ------------------------------- Name: Dr. Victor Bischoff ------------------------------- Vice Chairman and Director BIOTECH TARGET S.A. Date: November 19, 1998 By: /s/ DR. ANDREAS BREMER ------------------------------- Name: Dr. Andreas Bremer ------------------------------- Signatory Authority Date: November 19, 1998 By: /s/ DR. ANDERS HOVE ------------------------------- Name: Dr. Anders Hove ------------------------------- Signatory Authority Page 9 of 9 pages -----END PRIVACY-ENHANCED MESSAGE-----